Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis.

doi:10.1016/j.vaccine.2020.12.079

Paper

DOI: 10.1016/j.vaccine.2020.12.079

Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis.

Published Jan 13, 2021 · J. Van den Boogaard, B. de Gier, Priscila de Oliveira Bressane Lima

Vaccine

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Meta-Analysis

Rigorous Journal

Study Snapshot

One and two doses of rubella containing vaccines are highly immunogenic for a long period of time, effective in preventing rubella and congenital rubella syndrome, and safe.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/j.vaccine.2019.11.070

Safety profile of rubella vaccine administered to pregnant women: A systematic review of pregnancy related adverse events following immunisation, including congenital rubella syndrome and congenital rubella infection in the foetus or infant.

Inadvertent rubella vaccination during pregnancy is safe, with no evidence of vaccine-associated congenital rubella syndrome, but transplacental vaccine virus infection can occur.

2019·14citations·P. Mangtani et al.·Vaccine

Vaccine

DOI: 10.15585/mmwr.mm6842a1

Global Routine Vaccination Coverage, 2018

Global vaccination coverage for diphtheria, tetanus, and pertussis remained stable from 2010 to 2018, but improved for rotavirus, pneumococcal conjugate vaccine, rubella, and hepatitis B vaccines.

2019·142citations·M. Peck et al.·Morbidity and Mortality Weekly Report

Morbidity and Mortality Weekly Report

DOI: 10.1016/S1473-3099(19)30395-0

Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis

Measles vaccination in infants younger than 9 months induces a good immune response and is safe, but higher antibody titres and vaccine effectiveness are found when administered at older ages.

2019·55citations·L. N. Nic Lochlainn et al.·The Lancet. Infectious Diseases

The Lancet. Infectious Diseases

DOI: 10.1016/j.vaccine.2018.01.089

A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.

The refrigerator-stable VARIVAX vaccine has a similar safety, tolerability, and immunogenicity profile to the frozen formulation, making it a safe and effective vaccine for children aged 12 to 23 months.

2019·4citations·K. Reisinger et al.·Vaccine

Vaccine

DOI: 10.1016/S1473-3099(18)30650-9

Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.

Co-administration of measles-rubella and attenuated Japanese encephalitis vaccines at 8 months of age in China shows similar seroconversion and safety, supporting their use in infants aged 8 months.

2019·12citations·Yan Li et al.·The Lancet. Infectious diseases

The Lancet. Infectious diseases

Citations

DOI: 10.3390/vaccines12111258

Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.

The proposed Phase III trial framework for MR-MAPs aims to compare their immunogenicity and safety with subcutaneous measles-rubella vaccines in 9- to 10-month-old infants, aiming to generate clinical data for regulatory approval and WHO prequalification.

2024·1citation·Darin Zehrung et al.·Vaccines

Vaccines

DOI: 10.1016/S0140-6736(24)00532-4

A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial

The MRV-MNP microneedle patch is safe and immunogenic in children, supporting its accelerated development for low-income and middle-income countries.

2024·19citations·Ikechukwu Adigweme et al.·Lancet (London, England)

Lancet (London, England)

DOI: 10.1016/j.vaccine.2023.11.014

The path to eradication of rubella.

Routine vaccination of infants and surveillance for chronic infection can potentially eradicate rubella, with potential barriers being persistent in utero infections and immunosuppressed patients.

2023·6citations·S. Reef et al.·Vaccine

Vaccine

DOI: 10.1080/21645515.2023.2254536

Do adolescents need a rubella vaccination campaign? Rubella serosurvey among healthy children in Hangzhou, China

A catch-up dose of rubella vaccine is recommended for adolescents and young people aged over 14 years who have not yet been vaccinated due to a decreasing trend in antibody positivity and GMC.

2023·2citations·Xiaozheng Sandra Wang et al.·Human Vaccines & Immunotherapeutics

Human Vaccines & Immunotherapeutics

DOI: 10.1002/rmv.2416

Safety of varicella vaccination strategies: An overview of reviews

Varicella vaccination is safe for children aged 9 months to 6 years, with mild local and systemic reactions but rare serious adverse reactions.

2022·9citations·S. Ahern et al.·Reviews in Medical Virology

Reviews in Medical Virology